Tiger Brokers

US StockDetailed Quotes
Provided by Tiger Trade Technology Pte. Ltd.

Monte Rosa Therapeutics

14.26
-0.0100-0.07%
Volume:1.15M
Turnover:16.44M
Market Cap:1.22B
PE:-8.17
High:14.87
Open:14.28
Low:14.13
Close:14.27
52wk High:25.77
52wk Low:4.80
Shares:85.31M
Float Shares:54.48M
Volume Ratio:1.15
T/O Rate:2.10%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.7450
EPS(LYR):-0.4650
ROE:-42.66%
ROA:-21.63%
PB:2.50
PE(LYR):-30.67

Loading ...

OverviewCompanyNewsFilings

Monte Rosa Therapeutics Price Target Maintained with a $27.00/Share by Wedbush

Dow Jones
·
Yesterday

Novartis-Backed MRT-6160 Expansion and Strong Partnership Economics Underpin Oliver McCammon’s Buy Rating on Monte Rosa’s GLUE

TIPRANKS
·
Yesterday

Top Midday Stories: GE Aerospace to Acquire Consolidated Precision Products; Qualcomm Issues Share Warrant to Amazon

MT Newswires Live
·
Sep 08

Monte Rosa Therapeutics to receive $50M milestone payment from Novartis

TIPRANKS
·
Sep 08

Monte Rosa Says Novartis Starts Phase 2 Trial of MRT-6160 in Sjögren's Disease, Triggers USD 50 Million Milestone

Reuters
·
Sep 08

Monte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for Vav1-Directed Molecular Glue Degrader Mrt-6160 (Ddy391)

THOMSON REUTERS
·
Sep 08

Monte Rosa Therapeutics, - Eligible for Tiered Royalties on Ex-U.S. Net Sales of Mrt-6160

THOMSON REUTERS
·
Sep 08

Monte Rosa Therapeutics, - Novartis to Fund Phase 2; Monte Rosa to Co-Fund Phase 3 and Share 30% U.S. Profits/Losses

THOMSON REUTERS
·
Sep 08

Monte Rosa Therapeutics, - Eligible for up to $2.10 Bln in Milestones Starting with Phase 2 Initiation

THOMSON REUTERS
·
Sep 08

Monte Rosa Therapeutics, - to Receive $50 Mln Milestone Payment from Novartis for First Patient Visit

THOMSON REUTERS
·
Sep 08

Monte Rosa Grants Inducement Awards to New Hires, Including Options Priced at $14.31

Reuters
·
Sep 03

Monte Rosa Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Sep 03

Monte Rosa Therapeutics to Present at Wells Fargo Healthcare Conference Fireside Chat

Reuters
·
Sep 01

Monte Rosa Therapeutics (GLUE) Looks Pricey As Phase 2 Progress Keeps The Story Alive

Simply Wall St.
·
Aug 26

Monte Rosa Therapeutics Price Target Maintained with a $28.00/Share by Guggenheim

Dow Jones
·
Aug 25

Analysts Offer Insights on Healthcare Companies: Monte Rosa Therapeutics (GLUE) and Rhythm Pharmaceuticals (RYTM)

TIPRANKS
·
Aug 25

Monte Rosa Doses First Patient in Phase 2 MODeFIRe-1 Trial of MRT-2359 Plus Apalutamide in mCRPC

Reuters
·
Aug 24

Monte Rosa Therapeutics Announces First Patient Dosed in Modefire-1, a Phase 2 Study of Mrt-2359 in Combination with Apalutamide in Patients with Ar Mutation-Positive Metastatic Castration-Resistant Prostate Cancer

THOMSON REUTERS
·
Aug 24

Monte Rosa Therapeutics - to Provide Phase 1/2 Study Update on Mrt-2359 Plus Enzalutamide by Year-End

THOMSON REUTERS
·
Aug 24

Widening Losses And Profitability Swing Might Change The Case For Investing In Monte Rosa Therapeutics (GLUE)

Simply Wall St.
·
Aug 17
More